雌激素在非小细胞肺癌中的研究进展

Recent Advances in Association of Estrogen and Non-small Cell Lung Cancer

肺癌是目前发病率及死亡率最高的恶性肿瘤之一,其中约85%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。尽管其治疗手段不断提高,但总体预后不容乐观。既往研究已证实雌激素系统参与了NSCLC的发生、发展。越来越多的证据表明,抗雌激素治疗不仅可以逆转NSCLC患者对铂类化疗药物的耐药性,还可以增加人类表皮生长因子受体酪氨酸激酶抑制剂的疗效。本文就雌激素系统及抗雌激素治疗在NSCLC中的作用作一综述。

Lung cancer, of which approximately 85% are non-small cell lung cancer （NSCLC）, is one of the most prevalent cancers and the most leading cause of cancer mortality. Despite recent improvements in its treatment, the prognosis remains dismal. Previous studies have clearly proved that estrogen and estrogen receptors （ER） are involve in the pathogenesis and development of lung cancer. More and more evidences showed antiestrogen therapy may reverse the drug-resistance of platinum based chemotherapy in NSCLC patients and can enhance curative effect of epidermal growth factor receptor tyrosine kinase inhibitor. We will review recent progress in the function of estrogen in NSCLC and the treatment based on the ER sig-naling pathways for NSCLC in this article.